Cancer BiologyProceedings of the National Academy of SciencesPeer-reviewed
Pharmacological SOS1 inhibitor BI-3406 demonstrates in vivo anti-tumor activity comparable to SOS1 genetic ablation in KRAS mutant tumors
Fernando C. Baltanás, Maximilian Kramer‐Drauberg, Rósula García‐Navas…·Eugenio Santos
This study shows that the SOS1 inhibitor BI-3406 effectively reduces tumor growth in KRAS mutant cancers, similar to genetic SOS1 ablation, with comparable efficacy to another KRAS inhibitor.
16 citationstop 5%